IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v11y2020i1d10.1038_s41467-020-17873-3.html
   My bibliography  Save this article

HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice

Author

Listed:
  • Rouven Hoefflin

    (Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg)

  • Sabine Harlander

    (University of Zurich
    University of Zurich)

  • Silvia Schäfer

    (Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg
    University of Freiburg
    University of Freiburg)

  • Patrick Metzger

    (University of Freiburg
    Medical Centre—University of Freiburg, Faculty of Medicine, University of Freiburg)

  • Fengshen Kuo

    (Immunogenomics & Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center)

  • Désirée Schönenberger

    (University of Zurich
    University of Zurich)

  • Mojca Adlesic

    (Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg
    University of Freiburg)

  • Asin Peighambari

    (Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg
    University of Freiburg
    University of Freiburg)

  • Philipp Seidel

    (Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg
    University of Freiburg)

  • Chia-yi Chen

    (Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg)

  • Miguel Consenza-Contreras

    (Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg)

  • Andreas Jud

    (Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg)

  • Bernd Lahrmann

    (University of Heidelberg)

  • Niels Grabe

    (University of Heidelberg)

  • Danijela Heide

    (German Cancer Research Center (DKFZ))

  • Franziska M. Uhl

    (Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg
    University of Freiburg)

  • Timothy A. Chan

    (Immunogenomics & Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center)

  • Justus Duyster

    (Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg
    Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg)

  • Robert Zeiser

    (Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg
    University of Freiburg
    Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg)

  • Christoph Schell

    (Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg)

  • Mathias Heikenwalder

    (German Cancer Research Center (DKFZ))

  • Oliver Schilling

    (Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg
    Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg
    German Cancer Consortium (DKTK), Partner Site Freiburg, and German Cancer Research Center (DKFZ))

  • A. Ari Hakimi

    (Immunogenomics & Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center)

  • Melanie Boerries

    (Medical Centre—University of Freiburg, Faculty of Medicine, University of Freiburg
    Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg
    German Cancer Consortium (DKTK), Partner Site Freiburg, and German Cancer Research Center (DKFZ))

  • Ian J. Frew

    (Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg
    University of Zurich
    University of Zurich
    University of Freiburg)

Abstract

Mutational inactivation of VHL is the earliest genetic event in the majority of clear cell renal cell carcinomas (ccRCC), leading to accumulation of the HIF-1α and HIF-2α transcription factors. While correlative studies of human ccRCC and functional studies using human ccRCC cell lines have implicated HIF-1α as an inhibitor and HIF-2α as a promoter of aggressive tumour behaviours, their roles in tumour onset have not been functionally addressed. Herein we show using an autochthonous ccRCC model that Hif1a is essential for tumour formation whereas Hif2a deletion has only minor effects on tumour initiation and growth. Both HIF-1α and HIF-2α are required for the clear cell phenotype. Transcriptomic and proteomic analyses reveal that HIF-1α regulates glycolysis while HIF-2α regulates genes associated with lipoprotein metabolism, ribosome biogenesis and E2F and MYC transcriptional activities. HIF-2α-deficient tumours are characterised by increased antigen presentation, interferon signalling and CD8+ T cell infiltration and activation. Single copy loss of HIF1A or high levels of HIF2A mRNA expression correlate with altered immune microenvironments in human ccRCC. These studies reveal an oncogenic role of HIF-1α in ccRCC initiation and suggest that alterations in the balance of HIF-1α and HIF-2α activities can affect different aspects of ccRCC biology and disease aggressiveness.

Suggested Citation

  • Rouven Hoefflin & Sabine Harlander & Silvia Schäfer & Patrick Metzger & Fengshen Kuo & Désirée Schönenberger & Mojca Adlesic & Asin Peighambari & Philipp Seidel & Chia-yi Chen & Miguel Consenza-Contre, 2020. "HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice," Nature Communications, Nature, vol. 11(1), pages 1-21, December.
  • Handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-17873-3
    DOI: 10.1038/s41467-020-17873-3
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-020-17873-3
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-020-17873-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-17873-3. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.